JP2017536363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536363A5 JP2017536363A5 JP2017526853A JP2017526853A JP2017536363A5 JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5 JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- drug
- pharmaceutical combination
- fibrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102100028502 Transcription factor EB Human genes 0.000 claims 5
- 101710162524 Transcription factor EB Proteins 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 229940125753 fibrate Drugs 0.000 claims 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229930002330 retinoic acid Natural products 0.000 claims 3
- 235000019155 vitamin A Nutrition 0.000 claims 3
- 239000011719 vitamin A Substances 0.000 claims 3
- 229940045997 vitamin a Drugs 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical group CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229960002297 fenofibrate Drugs 0.000 claims 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 2
- 229960003627 gemfibrozil Drugs 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- 241000723347 Cinnamomum Species 0.000 claims 1
- 206010011777 Cystinosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 101150062178 Tfeb gene Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 230000004642 autophagic pathway Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- CRQQGFGUEAVUIL-UHFFFAOYSA-N chlorothalonil Chemical compound ClC1=C(Cl)C(C#N)=C(Cl)C(C#N)=C1Cl CRQQGFGUEAVUIL-UHFFFAOYSA-N 0.000 claims 1
- 208000024042 cholesterol ester storage disease Diseases 0.000 claims 1
- 208000013760 cholesteryl ester storage disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- 235000017803 cinnamon Nutrition 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 201000008049 fucosidosis Diseases 0.000 claims 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 230000002132 lysosomal effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- 201000002273 mucopolysaccharidosis II Diseases 0.000 claims 1
- 208000022018 mucopolysaccharidosis type 2 Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims 1
- 230000000153 supplemental effect Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081696P | 2014-11-19 | 2014-11-19 | |
| US62/081,696 | 2014-11-19 | ||
| PCT/US2015/060878 WO2016081365A1 (en) | 2014-11-19 | 2015-11-16 | Compositions and methods for treating lysosomal disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232644A Division JP2020100621A (ja) | 2014-11-19 | 2019-12-24 | リソソーム蓄積症治療のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536363A JP2017536363A (ja) | 2017-12-07 |
| JP2017536363A5 true JP2017536363A5 (enExample) | 2018-10-18 |
Family
ID=56014423
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526853A Pending JP2017536363A (ja) | 2014-11-19 | 2015-11-16 | リソソーム蓄積症治療のための組成物及び方法 |
| JP2019232644A Pending JP2020100621A (ja) | 2014-11-19 | 2019-12-24 | リソソーム蓄積症治療のための組成物及び方法 |
| JP2021063971A Active JP7752958B2 (ja) | 2014-11-19 | 2021-04-05 | リソソーム蓄積症治療のための組成物及び方法 |
| JP2021153206A Withdrawn JP2022003060A (ja) | 2014-11-19 | 2021-09-21 | リソソーム蓄積症治療のための組成物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232644A Pending JP2020100621A (ja) | 2014-11-19 | 2019-12-24 | リソソーム蓄積症治療のための組成物及び方法 |
| JP2021063971A Active JP7752958B2 (ja) | 2014-11-19 | 2021-04-05 | リソソーム蓄積症治療のための組成物及び方法 |
| JP2021153206A Withdrawn JP2022003060A (ja) | 2014-11-19 | 2021-09-21 | リソソーム蓄積症治療のための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170354666A1 (enExample) |
| EP (2) | EP4026545A1 (enExample) |
| JP (4) | JP2017536363A (enExample) |
| KR (1) | KR20170083146A (enExample) |
| CN (1) | CN107205976A (enExample) |
| AU (1) | AU2015350223B2 (enExample) |
| CA (2) | CA3176253A1 (enExample) |
| ES (1) | ES2914085T3 (enExample) |
| WO (1) | WO2016081365A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10493023B2 (en) | 2013-05-07 | 2019-12-03 | Seelos Therapeutics, Inc. | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
| CA3176253A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Use of cinnamic acid or sodium benzoate for treating lysosomal disorders |
| CN109563024B (zh) | 2016-06-13 | 2023-06-06 | 心悦生医股份有限公司 | 苯甲酸锂的共晶及其用途 |
| CN109563018A (zh) * | 2016-06-13 | 2019-04-02 | 心悦生医股份有限公司 | 苯甲酸钠的共晶及其用途 |
| US11020366B2 (en) * | 2016-12-29 | 2021-06-01 | Rush University Medical Center | Locomotor activity and increase in longevity of late infantile neuronal ceriod lipofuscinosis subjects by Gemfibrozil |
| JP6991246B2 (ja) * | 2017-02-08 | 2022-02-03 | ノバルティス アーゲー | Ｆｇｆ２１模倣抗体及びその使用 |
| WO2019152391A1 (en) * | 2018-01-30 | 2019-08-08 | Rush University Medical Center | Sequential staining for multiplex analyses of tissues and cells |
| JP7366408B2 (ja) * | 2018-02-06 | 2023-10-23 | 国立大学法人京都大学 | ライソゾーム病の予防及び治療剤 |
| US20210186937A1 (en) * | 2018-05-22 | 2021-06-24 | Duke University | Compositions and methods for treating neurodegenerative disorders with rifaximin |
| EP3876932A4 (en) * | 2018-11-05 | 2022-07-20 | Rush University Medical Center | Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases |
| MX2021008152A (es) * | 2019-01-03 | 2021-10-13 | Univ Pittsburgh Commonwealth Sys Higher Education | Metodos y materiales para aumentar los niveles del polipeptido del factor de transcripcion eb. |
| EA202192199A1 (ru) * | 2019-02-25 | 2021-12-17 | Раш Юниверсити Медикал Сентер | Композиции, содержащие коричную кислоту, и способы их применения |
| CN113811359A (zh) * | 2019-03-22 | 2021-12-17 | 拉什大学医学中心 | 用于溶酶体贮积症的经鼻基因递送和口服肉桂酸、油酰胺或吉非贝齐的组合 |
| CA3153963A1 (en) * | 2019-09-09 | 2021-03-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb |
| WO2021067243A1 (en) * | 2019-10-01 | 2021-04-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
| WO2022159086A1 (en) * | 2021-01-20 | 2022-07-28 | Rush University Medical Center | Improved treatment for globoid cell leukodsytrophy or krabbe disease |
| EP4447952A4 (en) * | 2021-12-16 | 2025-11-19 | Us Gov Veterans Affairs | Benzoic acid salts for the treatment of injuries and disorders of the nervous system |
| US12042476B2 (en) * | 2022-02-04 | 2024-07-23 | Mcmaster University | Methods for the treatment of lysosomal storage diseases |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2311356C (en) | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
| US20010028895A1 (en) | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
| KR101573316B1 (ko) * | 2004-03-29 | 2015-12-01 | 와이어쓰 엘엘씨 | 종합비타민 및 무기물 영양 보충제 |
| US20060135612A1 (en) * | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| ES2246737B1 (es) * | 2005-06-09 | 2006-12-01 | Jose Juan Rodriguez Jerez | "composicion farmaceutica que comprende lisina y usos correspondientes". |
| JP2009084155A (ja) * | 2006-01-16 | 2009-04-23 | Kanazawa Univ | レビー小体病治療薬及びレビー小体病予防薬 |
| US20070225360A1 (en) * | 2006-03-22 | 2007-09-27 | L'oreal | Anti-aging composition containing phloretin |
| GB0718824D0 (en) * | 2007-09-26 | 2007-11-07 | Univ Ramot | Methods of treating lysosomal storage disorders |
| US20120114670A1 (en) * | 2007-10-02 | 2012-05-10 | University Of Rochester | Methods and compositions related to synergistic responses to oncogenic mutations |
| US9388413B2 (en) * | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
| US9388414B2 (en) * | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
| JP2010106001A (ja) | 2008-10-31 | 2010-05-13 | Theravalues Corp | Ｐｐａｒ活性化剤 |
| EP2218458A1 (en) * | 2009-02-13 | 2010-08-18 | Fondazione Telethon | Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof |
| MX337933B (es) * | 2009-10-19 | 2016-03-29 | Amicus Therapeutics Inc | Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal. |
| JP2014511391A (ja) * | 2011-03-07 | 2014-05-15 | フォンダッツィオーネ・テレソン | Ｔｆｅｂリン酸化阻害剤およびその使用 |
| US9845327B2 (en) * | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| PL399467A1 (pl) * | 2012-06-08 | 2013-12-09 | 3G Therapeutics Inc. | Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS) |
| US9750712B2 (en) | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
| CA3176253A1 (en) * | 2014-11-19 | 2016-05-26 | Rush University Medical Center | Use of cinnamic acid or sodium benzoate for treating lysosomal disorders |
-
2015
- 2015-11-16 CA CA3176253A patent/CA3176253A1/en active Pending
- 2015-11-16 WO PCT/US2015/060878 patent/WO2016081365A1/en not_active Ceased
- 2015-11-16 CA CA2967066A patent/CA2967066A1/en active Pending
- 2015-11-16 JP JP2017526853A patent/JP2017536363A/ja active Pending
- 2015-11-16 AU AU2015350223A patent/AU2015350223B2/en active Active
- 2015-11-16 KR KR1020177016827A patent/KR20170083146A/ko not_active Ceased
- 2015-11-16 CN CN201580073947.8A patent/CN107205976A/zh active Pending
- 2015-11-16 EP EP22151969.7A patent/EP4026545A1/en active Pending
- 2015-11-16 EP EP15861122.8A patent/EP3220906B1/en active Active
- 2015-11-16 US US15/527,506 patent/US20170354666A1/en not_active Abandoned
- 2015-11-16 ES ES15861122T patent/ES2914085T3/es active Active
-
2019
- 2019-12-24 JP JP2019232644A patent/JP2020100621A/ja active Pending
-
2020
- 2020-09-29 US US17/036,138 patent/US12023345B2/en active Active
-
2021
- 2021-04-05 JP JP2021063971A patent/JP7752958B2/ja active Active
- 2021-09-21 JP JP2021153206A patent/JP2022003060A/ja not_active Withdrawn
-
2024
- 2024-06-04 US US18/733,348 patent/US20250134911A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536363A5 (enExample) | ||
| Pena-Altamira et al. | Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| Zhang et al. | Advances in the pathogenesis of steroid-associated osteonecrosis of the femoral head | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015503593A5 (enExample) | ||
| WO2012030160A3 (en) | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | |
| Dubey et al. | Recent studies on cellular and molecular mechanisms in Alzheimer’s disease: focus on epigenetic factors and histone deacetylase | |
| AU2012286851A8 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2014507476A5 (enExample) | ||
| JP2007277267A5 (enExample) | ||
| Cuadrado-Tejedor et al. | Epigenetic drugs in Alzheimer’s disease | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| JP2015529655A5 (enExample) | ||
| EP2849738A4 (en) | HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES | |
| JP2016518338A5 (enExample) | ||
| EA201491039A1 (ru) | Комбинации диацереина и нестероидных противовоспалительных лекарственных средств | |
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| Wang et al. | Current evidence on the role of lipid lowering drugs in the treatment of psoriasis | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2011090317A3 (en) | Imidazopyrazinone derivatives with apoptosis inducing activity on cells |